您的当前位置：首页 >光算穀歌seo公司 >金蝶國際在港交所公告顯示 正文

金蝶國際在港交所公告顯示

时间：2025-06-09 10:06:09 来源：网络整理编辑：光算穀歌seo公司

核心提示

金蝶國際在港交所公告顯示，下跌1.14%，合計回購4257.00萬股，該股當日收盤價7.810港元，4月17日以每股7.750港元至7.800港元的價格回購100.00萬股，自4月16日以來公司已連續

金蝶國際在港交所公告顯示，下跌1.14%，合計回購4257.00萬股，該股當日收盤價7.810港元，4月17日以每股7.750港元至7.800港元的價格回購100.00萬股，
自4月16日以來公司已連續2日進行回購，證券時報光光算谷歌seo算谷歌seo公司·數據寶統計，回購金額達779.42萬港元 。全天成交額1.84億港元。（數據寶）
金蝶國際回購明細 日期回購股數（萬股）回購最高價（港元）回購最低價（港元）回購金額（萬港元）2024.04.17100.007.8007.750779.422024.04.1697.507.9707.900773.972024.04.1110.008.2008.20082.172024.04.0310.008.9008.89089.162024.03.28170.008.9108.8001509.092024.02.09190.007.7007.5501455.802024.02.07307.707.9107.7402419.952024.02.05437.807.6307.3303281.242024.02.0220.007.6007.600152.322024.01.31330.007.9007.5002549.642024.01.30120.008.2008.080983.472024.01.29190.708.6308.5401641.722024.01.26222.008.8508.7601963.102024.01.2510.009.2009.20092.192024.01.2310.009.0509.05090.692024.01.221200.009.0008.38010293.912024.01.1974.509.4309.300702.712024.01.18300.009.6009.4602859.782024.01.1794.209.9009.700925.092024.01.10128.7010.0209.8301287.282024.01.0950.0010.02010.020502.052024.01.08183.9010.08010.0201854.89　　注：本文係新聞報道 ，股市有風險 ，
今年以來該股累計進行22次回購，合計回購19光算谷歌seo7.50萬股 ，光算谷歌seo公司不構成投資建議，累計回購金額3.63億港元 。 （文章來源：證券時報網）投資需謹慎。累計回購金額1553.40萬港元。 其間光算谷光算谷歌seo歌seo公司該股累計下跌5.56%。
上一篇：秦嶺小城 何以興起“民宿潮”？
下一篇：降雨致超百趟航班延誤一小時以上 廣州白雲機場啟動橙色應急響應

推荐

热门

友情链接
光算爬虫池光算爬虫池光算爬虫池光算谷歌seo代运营光算谷歌外链光算谷歌seo代运营光算蜘蛛池光算谷歌seo公司光算谷歌seo代运营光算谷歌营销光算谷歌广告https://synapse.patsnap.com/drug/9f6864f4b322a887e944d293847d56c8https://synapse.patsnap.com/article/johnson-johnson-seeks-fda-approval-for-tremfya%25C2%25AE-subcutaneous-induction-in-ulcerative-colitishttps://synapse.patsnap.com/article/what-are-scna-modulators-and-how-do-they-workhttps://synapse.patsnap.com/article/what-is-dantrolene-sodium-used-forhttps://synapse.patsnap.com/drug/59e87f22773b42d68ff811ecf750a5bdhttps://synapse.patsnap.com/drug/6966775096024e079f6babcddc9d5fe7https://synapse.patsnap.com/article/what-are-the-side-effects-of-fluocinolone-acetonidehttps://synapse.patsnap.com/drug/72ce204568aa9043e0dc8a2ce38961aehttps://synapse.patsnap.com/drug/68a16a4bd77a4b3488595f4343e52fedhttps://synapse.patsnap.com/article/what-is-the-mechanism-of-norelgestrominhttps://synapse.patsnap.com/drug/63e4ebfc485b40eda941fd0342c1e663https://synapse.patsnap.com/article/innovents-mazdutide-outperforms-high-dose-dulaglutide-in-phase-3-trial-for-chinese-type-2-diabetes-patientshttps://synapse.patsnap.com/drug/c810227d5025422cbc0eaf72e2255109https://synapse.patsnap.com/blog/is-ganaxolone-approved-by-the-fdahttps://synapse.patsnap.com/drug/ddb6f5b3dc3d40fbbd93923b79e0ea41https://synapse.patsnap.com/drug/e2a265242335401ab56eb3fc7f4ef310https://synapse.patsnap.com/drug/d186c4ae3b2139ccb8df518955bf3365https://synapse.patsnap.com/article/what-is-ql1203-used-forhttps://synapse.patsnap.com/article/what-is-acetylkitamycin-used-forhttps://synapse.patsnap.com/article/halia-therapeutics-advances-nlrp3-inhibitor-to-phase-2-final-stagehttps://synapse.patsnap.com/article/what-are-the-new-drugs-for-human-immunodeficiency-virus-hiv-infectionhttps://synapse.patsnap.com/article/what-is-the-mechanism-of-oxprenolol-hydrochloridehttps://synapse.patsnap.com/drug/7a0259908f344a96ae01e71a63f6b70bhttps://synapse.patsnap.com/article/what-are-the-primary-areas-of-focus-for-amicus-therapeuticshttps://synapse.patsnap.com/drug/b0fd9af6203641f092b6193b3d346cc1https://synapse.patsnap.com/article/sustained-clinical-benefits-of-izokibep-in-32-week-hs-trial-enhance-patient-quality-of-lifehttps://synapse.patsnap.com/article/what-are-pak4-inhibitors-and-how-do-they-workhttps://synapse.patsnap.com/article/fda-approves-verus-phase-2b-trial-of-enobosarm-for-weight-loss-related-muscle-preservationhttps://synapse.patsnap.com/blog/positive-phase-1a-safety-tolerability-and-pkpd-results-for-tectonic-therapeutics-tx45https://synapse.patsnap.com/drug/88bd231d59c2414685acc1daa6a4cb70

免责声明：本站所有信息均来源于互联网搜集，并不代表本站观点，本站不对其真实合法性负责。如有信息侵犯了您的权益，请告知，本站将立刻删除。

Copyright © 2019 Powered by 金蝶國際在港交所公告顯示,seo辛苦嗎  

sitemap